Alcohol-related Liver Disease - Nordic Bioscience Skip to content Webinars and blog Why Biomarkers? Contact Menu Biomarker Solutions Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Therapeutic areas Cardiovascular diseases Cardiovascular diseases Browse overview Atherosclerosis and myocardial infarction Cardiomyopathies Heart failure Dermatology Dermatology Browse overview Atopic dermatitis Hidradenitis suppurutiva Psoriasis Psoriatic arthritis Scleroderma (systemic sclerosis) Translational models in dermatology Gastrointestinal diseases Gastrointestinal diseases Browse overview CPa9-HNE (NordicCPa9-HNE™)—serum calprotectin Inflammatory bowel disease (IBD) Crohn’s disease Ulcerative colitis Intestinal fibrosis Celiac disease Eosinophilic esophagitis (EoE) Translational models in IBD Hepatic diseases Hepatic diseases Browse overview Alcohol-related liver disease End-stage liver disease Enhanced Liver Fibrosis (ELF) Test Immune-mediated liver diseases MASLD, SLD, and MASH Metabolic dysregulation Viral liver diseases Translational models in hepatic fibrosis Kidney diseases Kidney diseases Browse overview Chronic kidney disease (CKD) IgA nephropathy (Berger’s disease) Diabetic kidney disease (DKD) Lupus nephritis Translational models in kidney diseases Neuroscience Neuroscience Browse overview Alzheimer’s disease Parkinson’s disease Multiple sclerosis Obesity Obesity Browse overview Obesity Diabetes Enhanced Liver Fibrosis (ELF) Test Oncology Oncology Browse overview Immuno-oncology Tumor fibrosis Cancer-associated Fibroblasts (CAFs) Translational models in cancer Respiratory diseases Respiratory diseases Browse overview Chronic respiratory diseases ECLIPSE partnering project (COPD) Pulmonary fibrosis Translational models in pulmonary fibrosis Rheumatic diseases Rheumatic diseases Browse overview Axial spondyloarthritis (axSpA) Osteoarthritis (OA) Psoriatic arthritis Rheumatoid arthritis (RA) RheumaTrace™ Systemic lupus erythematosus (SLE) Systemic sclerosis Translational models in rheumatology What we offer Biomarker portfolio Browse our extensive ProteintFingerPrint™ biomarker portfolio and easily find the biomarkers and biomarker panels that are most relevant to your study. Explore our biomarker portfolio Laboratory Services Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Our lab solutions Browse overview Why choose our lab Central lab services Specialty lab solutions Accreditations Regulatory services Our services Lab solutions Browse our comprehensive laboratory services and discover specialized solutions tailored to your research needs. Explore our lab services Technology Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Technology Browse overview Nordic ProteinFingerPrint Technology™ FIB-NIT™ biomarker panel RheumaTrace™ NordicPRO-C3™ (PRO-C3) NordicPRO-C6™ (PRO-C6) CPa9-HNE (NordicCPa9-HNE™)—serum calprotectin Kit in a Box Translational models Measure specific protein fragments Our technology Utilize Nordic Bioscience's ProteinFingerPrint™ biomarker technology to measure specific protein fragments. Take a look at our technology About Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section About Browse overview About us News & events Board of directors Scientific leadership Business development Vision, mission & values Our collaborators and partners Code of Conduct Career Webinars and blog About Nordic Bioscience Who we are Learn about our history, leadership, and vision for the future. Stay updated with the latest news and events, discover career opportunities, and see how our expertise and strategic alliances shape the future of science. Explore Nordic Bioscience Publications Request a quote Menu Back Biomarker Solutions Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Cardiovascular diseases Cardiovascular diseases Browse overview Atherosclerosis and myocardial infarction Cardiomyopathies Heart failure Dermatology Dermatology Browse overview Atopic dermatitis Hidradenitis suppurutiva Psoriasis Psoriatic arthritis Scleroderma (systemic sclerosis) Translational models in dermatology Gastrointestinal diseases Gastrointestinal diseases Browse overview CPa9-HNE (NordicCPa9-HNE™)—serum calprotectin Inflammatory bowel disease (IBD) Crohn’s disease Ulcerative colitis Intestinal fibrosis Celiac disease Eosinophilic esophagitis (EoE) Translational models in IBD Hepatic diseases Hepatic diseases Browse overview Alcohol-related liver disease End-stage liver disease Enhanced Liver Fibrosis (ELF) Test Immune-mediated liver diseases MASLD, SLD, and MASH Metabolic dysregulation Viral liver diseases Translational models in hepatic fibrosis Kidney diseases Kidney diseases Browse overview Chronic kidney disease (CKD) IgA nephropathy (Berger’s disease) Diabetic kidney disease (DKD) Lupus nephritis Translational models in kidney diseases Neuroscience Neuroscience Browse overview Alzheimer’s disease Parkinson’s disease Multiple sclerosis Obesity Obesity Browse overview Obesity Diabetes Enhanced Liver Fibrosis (ELF) Test Oncology Oncology Browse overview Immuno-oncology Tumor fibrosis Cancer-associated Fibroblasts (CAFs) Translational models in cancer Respiratory diseases Respiratory diseases Browse overview Chronic respiratory diseases ECLIPSE partnering project (COPD) Pulmonary fibrosis Translational models in pulmonary fibrosis Rheumatic diseases Rheumatic diseases Browse overview Axial spondyloarthritis (axSpA) Osteoarthritis (OA) Psoriatic arthritis Rheumatoid arthritis (RA) RheumaTrace™ Systemic lupus erythematosus (SLE) Systemic sclerosis Translational models in rheumatology Laboratory Services Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Browse overview Why choose our lab Central lab services Specialty lab solutions Accreditations Regulatory services Technology Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Browse overview Nordic ProteinFingerPrint Technology™ FIB-NIT™ biomarker panel RheumaTrace™ NordicPRO-C3™ (PRO-C3) NordicPRO-C6™ (PRO-C6) CPa9-HNE (NordicCPa9-HNE™)—serum calprotectin Kit in a Box Translational models About Biomarker Solutions Learn how Nordic ProteinFingerPrint™ biomarkers can support your pipeline. Visit this section Biomarker Portfolio Find biomarkers and panels relevant to your study. Visit this section Kit in a Box Browse our convenient, lab-ready Kit in a Box products. Visit this section Why Biomarkers? Learn how biomarkers in general can benefit drug development. Visit this section Browse overview About us News & events Board of directors Scientific leadership Business development Vision, mission & values Our collaborators and partners Code of Conduct Career Webinars and blog Publications Request a quote Webinars and blog Why Biomarkers? Contact Home Hepatic Diseases Alcohol-related Liver Disease Alcohol-related Liver Disease Biomarkers in alcohol-related liver disease (ALD) The development and increase in liver fibrosis is a key component of alcohol-related liver disease (ALD), formerly known as alcoholic liver disease (ALD). This progression can result in cirrhosis or further develop into hepatocellular carcinoma and increased mortality. Patient monitoring using fibrosis biomarkers in ALD patients represents a potential novel diagnostic and disease management tool. Nordic Bioscience’s non-invasive biomarkers based on extracellular matrix (ECM) remodeling can help to overcome the challenges in diagnosing ALD and finding patients at high risk of disease progression. Furthermore, the use of predictive or prognostic biomarkers of the ECM to enrich or stratify patients likely to respond to a therapeutic in drug development trials may reduce the trial length, and size required to determine therapeutic efficacy. Publications ALD Nordic ProteinFingerPrint Technology™ alcohol-related liver disease biomarkers The hepatic extracellular matrix (ECM) is rich in different collagens, proteoglycans, and matricellular proteins. In alcohol-related liver disease, the disruption of the balance between degradation and formation of collagens results in ECM remodeling with net formation (build-up and scar formation) of the tissue. We have identified twenty types of collagens of relevance for liver health. These collagens have different structures and are distributed in different compartments of the ECM, therefore, have specific functions in the tissue. The dynamics of collagen turnover in alcohol-related liver fibrosis can be investigated using our biomarkers for the formation ( nordicPRO-C3™ , PRO-C4 , PRO-C5, nordicPRO-C6™ ) and degradation ( C3M , C4M , C5M, and C6M ) of collagens [ 1 ] . Browse our portfolio of liver biomarkers Clinical research value of ALD with nordicPRO-C3™, nordicPRO-C6™ and C4M Collagen formation of the interstitial matrix quantified by type III ( nordicPRO-C3™ ) and VI ( nordicPRO-C6™ ) collagens formation is elevated in ALD patients compared to healthy subjects (Ctrl). The basement membrane is further dysregulated in favor of degradation as seen by type IV collagen degradation ( C4M ) elevated in ALD patients (Figure 1). This heightened collagen formation in ALD patients suggests an ongoing tissue remodeling process within the interstitial matrix. This dysregulation of the basement membrane, characterized by elevated levels of type IV collagen degradation, underscores the complex interplay between collagen synthesis and degradation that contributes to the pathophysiology of ALD. Figure 1. nordicPRO-C3™, nordicPRO-C6™, C4M clinical research value, as presented at EASL 2019 by the GALAXY consortium Interested to learn more? Reach out! Biomarkers of portal hypertension in ALD ALD patients suffering from portal hypertension, measured by Hepatic venous pressure gradient (HPVG), have elevated levels of both formation and degradations biomarkers. This includes basement membrane (type IV collagen; PRO-C4 ) and interstitial matrix (type III collagens; nordicPRO-C3™ , type V collagen; C5M, Elastin; ELM) proteins (Figure 2.) Figure 2 . Formation and degradation biomarkers in alcoholic liver disease (ALD) [ 2 ] Nordic Bioscience’s biomarkers can be used to assess ALD severity by helping to identify patients with advanced fibrosis and to monitor the response to treatment and drug efficacy. We are happy to have our team of scientists discuss and understand your aims to select the most appropriate biomarkers that can help answer your research questions. Prognostic value and prediction of outcomes in ALD NordicPRO-C3™ and nordicPRO-C6™ provide insights into the liver function of ALD patients and nordicPRO-C3™ has prognostic value for predicting outcomes and liver-related events (LRE) in patients with ALD. NordicPRO-C3™ showed prediction value to identify which patients from a mixed-etiology cohort composed of patients with chronic hepatitis virus and compensated cirrhosis with or without a history of acute alcohol consumption (ALD) are at risk of liver-related outcomes [ 3 ] . As part of the GALAXY consortium , a prediction model was developed [ 4 ] based on nordicPRO-C3™ and independent predictors of LREs (platelets, AST/ALT) named ALPACA score which presented a superior prognostic performance for predicting LREs when compared to other liver scores currently used in the clinic such as ELF , TE, and FIB-4, see reference. With the ALPACA score, it was possible to differentiate between patients with a low and high risk of LREs. Browse our liver biomarkers About alcohol-related liver disease What is alcohol-related liver disease? Alcohol-related liver disease (ALD), formerly known as alcoholic liver disease, is a generic term for liver damage caused by chronic alcohol abuse. Prolonged excessive alcohol consumption can impair the liver’s ability to regenerate and lead to liver damage. Alcoholic liver disease is usually divided into 3 stages: alcoholic fatty liver disease, alcoholic hepatitis and cirrhosis, depending on the degree of fat accumulation, inflammation, and fibrosis. How many people have alcohol-related liver disease? The prevalence of alcohol-related related liver disease varies around the world, as the amount of alcohol consumed generally depends on cultural acceptance. In the United States, an estimated 3-5% of people suffer from some degree of alcoholic liver disease. How is alcohol-related liver disease treated? Currently, there is no specific treatment for alcoholic liver disease and the most successful intervention is the cessation of alcohol consumption. Abstaining from alcohol reduces the risk of further damage to the liver to a level where there is a chance that the liver will recover. With lifestyle changes, nonalcoholic steatohepatitis is reversible. However, in alcoholic steatohepatitis, liver transplantation may be required in severe cases, such as decompensated cirrhotics. How is alcohol-related liver disease diagnosed? Diagnosis of alcohol-related related liver disease relies on blood tests to assess liver function and alcohol consumption questionnaires. If blood tests indicate decreased liver function and advanced liver damage, further testing including imaging and liver biopsies may be required to determine the pathology of steatohepatitis. Get in touch Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly. +45 4452 5252 Contact us via email! Your scientific area Select area Cardiology Dermatology Gastroenterology Hepatology Nephrology Neurology Obesity Pulmonology Rheumatology Multi-organ/Other Your request Select request General inquiry Biomarkers Laboratory Something else First name Last name Email Company/Organization (optional) Phone (optional) Your message (optional) Nordic Bioscience ApS and its non-profit partner, The Extracellular Matrix Pharmacology Congress, can contact me by email with news on research, events, products, and similar. I can always withdraw my consent at any time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Nordic Bioscience’s assays, products, and services are for research use only and are not intended for medical or diagnostic purposes . News Fibroblast Activity and ECM Turnover | Webinar February 9, 2026 Read article Autumn Conference Season (Q3-Q4) September 10, 2025 Read article Nordic Bioscience Launches New Website June 16, 2025 Read article 1 2 3 … 15 Upcoming events AD/PD 2026 March 17, 2026 – March 21, 2026 Copenhagen, Denmark View event News, events, and other resources Discover Nordic Bioscience News & Events Get up to date with our news and events Blog Browse our articles, webinars, and videos Nordic Bioscience Explore our growing library of 750+ scientific publications Join our upcoming fibroblast activity webinar! Close Herlev Hovedgade 205 2730 Herlev Denmark (VAT: DK30799968) Subscribe to our newsletter! Therapeutic areas Cardiovascular diseases Dermatology Gastrointestinal diseases Hepatic diseases Kidney diseases Neuroscience Obesity and metabolic disorders Oncology Respiratory diseases Rheumatic diseases About About us News & events Board of Directors Scientific leadership Alliance managers Vision, mission & values Career Knowledge hub Technology The Nordic ProteinFingerPrint Technology™ The FIB-NIT™ Biomarker Panel RheumaTrace™ CPa9-HNE (Serum Calprotectin) Translational models Biomarker portfolio Whistleblower policy Cookie policy Privacy policy Site disclaimer Code of Conduct

Nordic Bioscience’s non-invasive biomarkers based on extracellular matrix (ECM) remodeling can help to overcome the challenges in diagnosing ALD and finding patients at high risk of disease progression.

…onitoring using fibrosis biomarkers in ALD patients represents a potential novel diagnostic and disease management tool. Nordic Bioscience’s non-invasive biomarkers based on extracellular matrix (ECM) remodeling can help to overcome the challenges in diagnosing ALD and finding patients at high risk of disease progression . Furthermore, the use of predictive or prognostic biomarkers of the ECM to enrich or stratify patients likely to respon…

Furthermore, the use of predictive or prognostic biomarkers of the ECM to enrich or stratify patients likely to respond to a therapeutic in drug development trials may reduce the trial length, and size required to determine therapeutic efficacy.

…modeling can help to overcome the challenges in diagnosing ALD and finding patients at high risk of disease progression. Furthermore, the use of predictive or prognostic biomarkers of the ECM to enrich or stratify patients likely to respond to a therapeutic in drug development trials may reduce the trial length, and size required to determine therapeutic efficacy . Publications ALD Nordic ProteinFingerPrint Technology™ alcohol-related liver disease biomarkers The hepatic extracellu…

No supporting quote found.